We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

BioLineRx to Announce Results of Phase II/III Trial for BL-1020 During Week of March 18, 2013

News   Jan 08, 2013

 
BioLineRx to Announce Results of Phase II/III Trial for BL-1020 During Week of March 18, 2013
 
 
 

RELATED ARTICLES

Evidence Reinforcing Approval of New Cancer Drugs Raises Questions

News

Around half of trials that supported new cancer drug approvals in Europe between 2014 and 2016 were judged to be at high risk of bias, according to a new study.

READ MORE

Treating Blood Cancers With a Low-cost Arthritis Drug

News

A simple arthritis drug could be an effective, low-cost solution to treat patients with blood cancers, according to a new study by the University of Sheffield.

READ MORE

Discontinuing Oral Immunotherapy for Peanut Allergy Reduces Its Protective Effects

News

A study has followed participants after oral immunotherapy (OIT) for peanut allergy have found that discontinuing OIT or continuing OIT at a reduced dose led to a decline in its protective effects.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE